-+ 0.00%
-+ 0.00%
-+ 0.00%

Zealand Pharma's Short-bowel Syndrome Drug Recommended for EU Approval

MT Newswires·09/18/2026 07:33:57
Listen to the news
07:33 AM EDT, 09/18/2026 (MT Newswires) -- Zealand Pharma's (ZEAL.CO) short-bowel syndrome drug Zeydovio was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use, according to a Friday notice. Zeydovio, a glepaglutide, increases intestinal and portal blood flow and inhibits gastric acid secretion and intestinal motility, while reducing patients' need for parenteral support. The drug is subject to final approval from the European Commission.